ARHGAP45 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

GO_0007165Biological processsignal transduction
GO_0051056Biological processregulation of small GTPase mediated signal transduction
GO_0090630Biological processactivation of GTPase activity
GO_0032587Cellular componentruffle membrane
GO_0035578Cellular componentazurophil granule lumen
GO_0034774Cellular componentsecretory granule lumen
GO_0005829Cellular componentcytosol
GO_0005576Cellular componentextracellular region
GO_0005886Cellular componentplasma membrane
GO_0016020Cellular componentmembrane
GO_0005515Molecular functionprotein binding
GO_0046872Molecular functionmetal ion binding
GO_0005096Molecular functionGTPase activator activity

IV. Literature review

[source]
Gene nameARHGAP45
Protein nameARHGAP45
HMHA1 protein
Rho GTPase-activating protein 45 [Cleaved into: Minor histocompatibility antigen HA-1 (mHag HA-1)]
Rho GTPase activating protein 45
SynonymsHMHA1
KIAA0223
DescriptionFUNCTION: Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. .; FUNCTION: Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL. .

AccessionsENST00000587602.5
ENST00000539243.6 [Q92619-2]
Q8IYN3
ENST00000313093.7 [Q92619-1]
ENST00000591169.2
ENST00000543365.5
F5H1R4
K7EM55
K7ES92
K7EQA4
ENST00000586866.5
ENST00000590214.5
ENST00000590577.2
K7EM85
A0A087X1A3
A0A2X0U2E5
Q92619
K7ES98
ENST00000587186.5